{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ziv-aflibercept",
    "query": {
      "intervention": "Ziv-aflibercept"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 260,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ziv-aflibercept&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T14:54:52.140Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05275205",
      "title": "Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "UBX1325 injection 50 μL",
          "type": "DRUG"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Unity Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2022-03-02",
      "completion_date": "2023-07-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 14,
      "location_summary": "Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05275205"
    },
    {
      "nct_id": "NCT01724554",
      "title": "Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Retinal Vein Occlusion",
        "Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthalmic Consultants of Boston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-11",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-05-22",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01724554"
    },
    {
      "nct_id": "NCT07630649",
      "title": "Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD"
      ],
      "interventions": [
        {
          "name": "Ixo-vec",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2026-06-02",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07630649"
    },
    {
      "nct_id": "NCT02689518",
      "title": "EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal aflibercept injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-04",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02689518"
    },
    {
      "nct_id": "NCT02457026",
      "title": "Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        },
        {
          "name": "Verteporfin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-01",
      "completion_date": "2018-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02457026"
    },
    {
      "nct_id": "NCT05989126",
      "title": "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "aflibercept 8 mg PFS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2024-04-15",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 2,
      "location_summary": "Bellaire, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05989126"
    },
    {
      "nct_id": "NCT00369655",
      "title": "VEGF Trap in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2007-01",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-05",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369655"
    },
    {
      "nct_id": "NCT06132035",
      "title": "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-related Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "CG-P5 peptide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept Injection [Eylea]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Caregen Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2023-12-22",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 7,
      "location_summary": "Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more",
      "locations": [
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06132035"
    },
    {
      "nct_id": "NCT00036946",
      "title": "VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "25 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036946"
    },
    {
      "nct_id": "NCT05536973",
      "title": "Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ADVM-022",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2022-08-23",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-09-18T14:54:52.140Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05536973"
    }
  ]
}